

Electronic prescribing system design priorities for antimicrobial stewardship: a cross-sectional survey of 142 UK infection specialists

Journal:	<i>Journal of Antimicrobial Chemotherapy</i>
Manuscript ID	JAC-2016-1044.R1
Manuscript Type:	Original Article
Date Submitted by the Author:	n/a
Complete List of Authors:	<p>Hand, Kieran; University Hospital Southampton NHS Foundation Trust, Southampton Pharmacy Research Centre, Southampton General Hospital; University of Southampton, Faculty of Health Sciences</p> <p>Cumming, Debbie; Isle of Wight NHS Trust, Pharmacy Department</p> <p>Hopkins, Susan; Royal Free London NHS Foundation Trust, Department of Infectious Diseases & Microbiology</p> <p>Ewings, Sean; University of Southampton, Southampton Statistical Sciences Research Institute</p> <p>Fox, Andy; University Hospital Southampton NHS Foundation Trust, Southampton Pharmacy Research Centre, Southampton General Hospital</p> <p>Theminiulle, Sandya; Isle of Wight NHS Trust, Microbiology Department</p> <p>Porter, Robert; Royal Devon and Exeter NHS Foundation Trust, Department of Microbiology</p> <p>Parker, Natalie; Hampshire Hospitals NHS Foundation Trust, Pharmacy Department, Royal Hampshire County Hospital</p> <p>Munns, Joanne; Western Sussex Hospitals NHS Foundation Trust, Pharmacy Department, St. Richard's Hospital</p> <p>Sheikh, Adel; Portsmouth Hospitals, Pharmacy</p> <p>Keyser, Taryn; Hampshire Hospitals NHS Foundation Trust, Pharmacy Department, Basingstoke and North Hampshire Hospital</p> <p>Puleston, Richard; Nottingham City Hospital, Institute of Public Health</p>
Keywords:	Antibiotic prescription, Computerised provider order entry, Clinical decision support systems

SCHOLARONE™
Manuscripts

1 **Article title: Electronic prescribing system design priorities for antimicrobial stewardship: a cross-**
2 **sectional survey of 142 UK infection specialists**

3

4 **Authors:**

5 Kieran S. Hand^{1,2*}, Debbie Cumming³, Susan Hopkins⁴, Sean Ewings⁵, Andy Fox^{1,2}, Sandya
6 Theminiulle⁶, Robert J. Porter⁷, Natalie Parker⁸, Joanne Munns⁹, Adel Sheikh¹⁰, Taryn Keyser¹¹,
7 Richard Puleston¹²

8

9 **Addresses:**

- 10 1. Southampton Pharmacy Research Centre, University Hospital Southampton NHS Foundation Trust,
11 Tremona Road, Southampton, SO16 6YD
12 2. Faculty of Health Sciences, University of Southampton, Southampton, UK, SO17 1BJ.
13 3. Pharmacy Department, St Mary's Hospital, Parkhurst Road, Newport, Isle of Wight, PO31 7QJ
14 4. Department of Infectious Diseases & Microbiology, Royal Free London NHS Foundation Trust,
15 Pond St, London, NW3 2QG
16 5. Southampton Statistical Sciences Research Institute, University of Southampton, University Road,
17 Southampton, SO17 1BJ
18 6. Microbiology Department, St Mary's Hospital, Parkhurst Road, Newport, Isle of Wight, PO31 7QJ
19 7. Department of Microbiology, Royal Devon and Exeter NHS Foundation Trust, Church lane,
20 Heavitree, Exeter, EX2 5AD, UK
21 8. Pharmacy Department, Hampshire Hospitals NHS Foundation Trust, Royal Hampshire County
22 Hospital, Romsey Road, Winchester, Hampshire, SO22 5DG
23 9. Pharmacy Department, Western Sussex Hospitals NHS Foundation Trust, St Richards Hospital,
24 Chichester, PO19 6SE
25 10. Pharmacy Department, Queen Alexandra Hospital, Portsmouth Hospitals' NHS Trust, Southwick
26 Hill Road, Portsmouth, PO6 3LY, UK

27 11. Pharmacy Department, Hampshire Hospitals NHS Foundation Trust, Basingstoke and North
28 Hampshire Hospital, Aldermaston Road, Basingstoke, Hampshire, RG24 9NA

29 12. Institute of Public Health, City Hospital, Nottingham, NG5 1PB

30 ***Corresponding author (telephone, fax and e-mail contact details):** Kieran S. Hand, telephone
31 02381205117, fax 02381203237, e-mail K.Hand@soton.ac.uk

32

33 **Short running title:** E-prescribing software features for antimicrobial stewardship

34

35 **3-5 keywords (very general terms such as 'bacteria' and 'human' and terms already present in the**

36 **title should be avoided, as should non-standard abbreviations):** CPOE, prescription, **Clinical**

37 **Decision Support Systems**

38

39 Synopsis

40 The implementation of electronic prescribing and medication administration systems (EPMAs) is a
41 priority for hospitals and a potential component of antimicrobial stewardship (AMS).

42 Objectives

43 This study aimed to identify software features within EPMAs that could potentially facilitate AMS
44 and to survey practising UK infection specialist healthcare professionals in order to assign priority to
45 these software features.

46 Methods

47 A questionnaire was developed using nominal group technique and transmitted via email links
48 through professional networks. The questionnaire collected demographic data, information on
49 priority areas and anticipated impact of EPMA. Responses from different respondent groups were
50 compared using the Mann Whitney U test.

51 Results

52 Responses were received from 164 individuals (142 analysable). Respondents were predominantly
53 specialist infection pharmacists (48%) or medical microbiologists (37%). 59% of pharmacists had
54 experience of EPMA in their hospitals compared to 35% of microbiologists. Pharmacists assigned
55 higher priority to: indication prompt ($p < 0.001$), allergy checker ($p = 0.003$) treatment protocols
56 ($p = 0.003$), drug-indication mismatch alerts ($p = 0.031$) and prolonged course alerts ($p = 0.041$); and
57 lower priority to a dose checker for adults ($p = 0.02$) and an interaction checker ($p < 0.05$), than
58 microbiologists. A "soft stop" functionality was rated essential or a high priority by 89% of
59 respondents. Potential EPMA software features were expected to have the greatest impact on
60 stewardship, treatment efficacy and patient safety outcomes with lowest impact on *Clostridium*
61 *difficile* infection (CDI), antimicrobial resistance and drug expenditure.

62 Conclusions

63 The survey demonstrates key differences in health professionals' opinions of different healthcare
64 benefits of EPMA but a consensus of anticipated positive impact on patient safety and antimicrobial
65 stewardship.

Confidential: for peer review only

66 **INTRODUCTION**

67 Antimicrobial resistance (AMR) is a major threat to public health and a significant resource and cost
68 burden on the United Kingdom (UK) National Health Service (NHS).¹ The Chief Medical Officer's 2013
69 report on infections and the rise of AMR called for action to preserve the effectiveness of existing
70 antimicrobials through antimicrobial stewardship (AMS).¹ The 2013 UK Five Year Antimicrobial
71 Resistance Strategy from the Department of Health (DH) also highlights AMS as one of seven key
72 areas for action and NHS England has subsequently introduced antimicrobial prescribing reduction
73 goals for English hospitals through the Commissioning for Quality and Innovation (CQUIN)
74 programme for 2016/17.^{2,3}

75
76 In 2012, the UK Department of Health commissioned a study of the potential benefits to staff and
77 patients of greater use of digital and information technology in the NHS and social care.⁴ The study
78 report identified four priority actions, one of which was to drive the rollout and use of electronic
79 prescribing (e-prescribing) in secondary care. Implementation of e-prescribing systems in hospitals
80 presents a unique opportunity to improve the quality of antimicrobial prescribing and to facilitate
81 AMS.⁵⁻¹⁰ Evidence for the benefits of AMS functionality within e-prescribing systems comes from
82 published research studies demonstrating positive impact on outcomes including increased guideline
83 adherence^{11,12} and effective initial therapy¹³ or reductions in antimicrobial prescribing,^{14,15}
84 resistance,^{16,17} dosing errors,⁸ length of hospital or ICU stay^{14,18} and mortality.^{12,13,19} However,
85 many of these information systems were created on a small scale in individual hospitals or groups of
86 institutions and few reports cover the full potential range of software features that enable AMS.
87 Moreover there does not appear to be a recognised standard to guide the specification and
88 commissioning of an optimal e-prescribing system that includes the required AMS functionality
89 appropriate for the challenges that health systems currently face worldwide.²⁰

90

91 This report presents results from a cross-sectional survey of UK infection specialist health
92 professionals. The specific objectives of this study were: to identify, using a convenience sample of
93 local infection experts (the nominal group technique), software features within NHS hospital e-
94 prescribing systems that could potentially facilitate antimicrobial stewardship; to assign a priority to
95 these software features according to the opinions of practising infection specialist healthcare
96 professionals; to identify any differences in priority setting according to professional group, hospital
97 status (teaching or district general) or previous experience of e-prescribing systems; and to
98 communicate research findings to e-prescribing software manufacturers and healthcare policy
99 makers.

100

101 MATERIALS AND METHODS

102 Two focus group meetings of experienced infection health professionals from a local network of
103 hospitals in the south central region of England were convened in order firstly, to identify software
104 features within existing e-prescribing and medicines administration (EPMA) systems that facilitate
105 AMS and secondly, to identify additional software features with the potential to facilitate AMS. The
106 focus groups had representation from six infection hospital pharmacists (three with experience of
107 EPMA systems), two consultant medical microbiologists (one with experience of EPMA systems) and
108 one EPMA analyst. The focus group meeting output was a list of software features to be included in
109 a questionnaire for wider circulation among UK infection specialist health professionals. Following
110 the focus groups, two infection pharmacists designed a questionnaire using SurveyMonkey®
111 software. The questionnaire included 42 questions, which were divided into 4 domains. The first
112 domain collected respondent demographic data including professional group, experience in a
113 specialist role, hospital setting and EPMA experience. In the remaining three domains, respondents
114 were asked to assign a priority to individual software features grouped according to the categories
115 of prescribing alerts/prompts (12 features), active prescription surveillance (11 features) and
116 prescribing trend surveillance (8 features). At the end of each domain, respondents were asked to

117 express their opinion of the anticipated collective impact of the software features from each domain
118 on a number of clinical, microbiological and process outcomes. For the prescribing trend surveillance
119 domain, respondents were asked to prioritise a number of technical aspects of the proposed
120 surveillance reports. Finally, the questionnaire provided a freetext narrative section inviting
121 respondents to suggest additional software features with potential to facilitate AMS, not mentioned
122 earlier in the survey. The questionnaire was piloted in the local region, predominately with infection
123 pharmacists and one medical microbiologist in October 2014. Feedback from the pilot led to the
124 incorporation of one additional category (work efficiency) to the list of process outcomes. A copy of
125 the finalised questionnaire and covering letter to respondents is available as an online Supplement
126 (S1).

127

128 Respondents were advised that participation was voluntary and anonymous, that the questionnaire
129 would take approximately 10-12 minutes to complete and that the results would be disseminated to
130 e-prescribing software manufacturers, policy makers and the clinical infection community. The
131 research team took the decision not to collect personal details of respondent names and employers
132 in order to elicit candid responses; although respondent internet protocol (IP) addresses were
133 collected, identifying responses from the same healthcare organisations. A hyperlink to the online
134 questionnaire was distributed via health professional networks including the UK Clinical Pharmacy
135 Association, the Royal College of Pathologists, the British Society for Antimicrobial Chemotherapy
136 and Public Health England. The online questionnaire was closed in July 2015, 7 months from launch.
137 Table 1 presents a glossary of key terms used in the questionnaire that will be referred to
138 throughout this report.

139

140 **Analysis methods**

141 Questionnaire data were summarised with descriptive statistics and analysed using IBM SPSS v.22
142 with priority ranking of software features by different groups of respondents compared using the

143 Mann Whitney U test. The respondent groups compared were: specialist pharmacists versus medical
144 microbiologists (the number of respondents from other professional groups was too few for
145 statistical analysis); respondents from hospitals with EPMA experience versus those without; and
146 respondents from teaching hospitals versus district general hospitals (DGHs). A p-value of <0.05 was
147 considered statistically significant. Finally, the freetext narrative comments were analysed by using
148 a summative approach to qualitative content analysis, grouping responses into common themes
149 according to frequency of reporting.²¹

150

151 This research did not require NHS Research Ethics Committee approval for sites in England, Scotland,
152 Wales or Northern Ireland according to the Health Research Authority online decision tool
153 (<http://www.hra-decisiontools.org.uk/ethics/>).

154

155 RESULTS

156 Respondent accountability

157 Responses were received from 164 individuals from 79 unique IP addresses. Twenty-two response
158 sets were removed from the dataset (11 pharmacists, 6 medical microbiologists, one ID physician, 4
159 nurses and one trainee) due to failure to complete responses to survey questions beyond
160 demographics. Responses from the remaining 142 individuals from 68 unique IP addresses were
161 included in the analysis. Eleven of these 142 did not complete all sections of the questionnaire and
162 missing data were ignored as they comprised less than 10% of responses.

163

164 Respondent demographics

165 The demographic profile of the 142 respondents included in the analysis is presented in Figure1.
166 Infection pharmacists comprised almost half of respondents (48%; 68/142) from 39 IP addresses and
167 the majority had at least 5 years' experience in a specialist infection role (47/68). Medical
168 microbiologists represented over one-third of respondents (37%; 53/142) from 35 IP addresses and

169 most had at least 5 years' experience (48/53). Six infectious diseases (ID) physicians responded to
170 the survey and a further six respondents were grouped as other healthcare professionals (medical
171 virologist, epidemiologist, junior doctor, infection prevention nurse, surveillance nurse and a
172 consultant in public health).

173

174 Fifty-two per cent of respondents were from **DGHs** (71/136 responses) and 45% from teaching
175 hospitals (61/136 responses). Figure 2 illustrates the distribution of experience of EPMA and e-
176 prescribing systems amongst the questionnaire respondents. **Half** of respondents (49%; 68/139)
177 reported experience of EPMA or e-prescribing; 59% of 68 infection pharmacists had experience of
178 EPMA in their hospitals compared to 35% of 52 microbiologists. Forty per cent (56/139) expected
179 implementation of EPMA within 5 years (25 from teaching hospitals and 29 from district general
180 hospitals) but 11% (15/139) did not expect EPMA within 5 years (5 from teaching hospitals and 9
181 from district general hospitals).

182

183 **Prescribing Prompt Software Features**

184 Table 2 presents survey response data for priority attributed by respondents to 12 software features
185 of EPMA systems grouped within the Prescribing Prompt category. **With the exception of restriction**
186 **features, all prescribing prompt software features were considered essential or high-priority by the**
187 **majority (>50%) of respondents.** The features considered essential by more than **50%** of respondents
188 were: an allergy checking function **and** a prompt to prescribers to record the clinical indication for
189 prescribing an antimicrobial.

190

191 **In comparison with medical microbiologists, specialist** pharmacists assigned higher priority to:
192 indication prompt ($p<0.001$); allergy checker ($p=0.003$); and treatment protocols ($p=0.003$) (Table 3).
193 Medical microbiologists assigned higher priority to a dose checker for adults ($p=0.023$) and an

194 interaction checker ($p < 0.05$). Respondents from hospitals with EPMA experience assigned higher
195 priority to an indication prompt ($p = 0.049$); whereas respondents from hospitals without EPMA
196 experience assigned higher priority to: restricted antimicrobial block ($p = 0.011$); dose checker for
197 children ($p = 0.024$); and blood level monitoring alert ($p = 0.033$). When responses from teaching
198 hospitals were compared with responses from DGHs, there were no statistically significant
199 differences in opinions of priority for any of the prescribing prompt software features. The majority
200 of respondents considered that both patient safety (60%; 84/140) and ability to deliver antimicrobial
201 stewardship (64%; 89/140) were extremely likely to be improved (Figure 3).

202

203 **Active Prescription Surveillance Software Features**

204 Table 4 presents survey response data for priority attributed by respondents to 11 software features
205 of EPMA systems grouped within the Active Prescription Surveillance category. All but two of the 11
206 features (daily reports of new or ongoing prescriptions of all antimicrobials) were considered
207 essential or high priority by the majority (>50%) of respondents. Only one feature was considered
208 essential by more than 50% of respondents: daily report of new prescriptions for critical
209 antimicrobials.

210

211 Specialist pharmacists assigned higher priority to a daily report of mismatch between prescribed
212 antimicrobial and associated indication ($p = 0.031$) and long IV/oral courses ($p = 0.041$) in comparison
213 to medical microbiologists (Table 3). Respondents from hospitals with EPMA experience (in
214 comparison to those without) assigned higher priority to: a daily report of newly-prescribed critical
215 antimicrobials ($p = 0.015$); and a daily report of any newly-prescribed antimicrobial ($p = 0.024$). When
216 responses from teaching hospitals were compared with responses from DGHs, there were no
217 statistically significant differences in opinions of priority for any of the active prescription

218 surveillance software features. The majority (>50%) of respondents considered that both patient
219 safety (53%; 71/135) and ability to deliver antimicrobial stewardship (60%; 80/134) were extremely
220 likely to be improved (Figure 4). Two respondents expressed the view that an improvement in
221 outcomes was extremely unlikely: one for reduction in expenditure on drugs; and one for reduction
222 in risk of *Clostridium difficile*.

223

224 Prescribing Trend Surveillance Software Features

225 Prescribing trend surveillance reports as a software feature were generally considered by
226 respondents to be of lower priority compared with prescribing prompts and active prescription
227 surveillance, with no trend surveillance software feature rated as essential by more than 50% of
228 respondents (Table 5). However, the majority of respondents did consider all of the proposed trend
229 surveillance features to be at least high priority. There were no statistically significant differences in
230 opinions of priority for prescribing trend surveillance software features between specialist
231 pharmacists and medical microbiologists, nor between respondents with or without EPMA
232 experience. Respondents from DGHs assigned a higher priority to the report of trends in proportion
233 of stat doses where administration was delayed software feature ($p=0.034$) (Table 3). The majority
234 of respondents considered that the prescribing trend surveillance group of software features would
235 be likely or extremely likely to have a positive impact on all of the listed clinical, microbiological and
236 process outcomes (Figure 5). More than 90% of respondents anticipated a positive impact on their
237 ability to deliver AMS.

238

239 Respondent opinions of selected technical aspects of prescribing trend surveillance reporting are
240 summarised in Table 6. Respondents expressed equal preference for patient days or patient
241 admissions as an activity denominator. A preference for annual and quarterly reporting intervals
242 rather than more frequent reports was evident. Surveillance reports for the whole hospital and by

243 clinical speciality or hospital department were rated more highly than reports by hospital ward or
244 individual responsible consultant physician. Finally, surveillance reports of prescribing and
245 administration of individual antimicrobials, by antimicrobial drug class and by locally defined drug
246 groups such as broad-spectrum agents were rated most highly by respondents with reports grouped
247 by route of administration considered of lesser importance.

248

249 **Freetext narrative responses**

250 Thirty-five respondents recorded narrative responses when prompted to submit suggestions for
251 additional software features not included in the questionnaire and 69 unique statements were
252 identified and grouped into nine common themes, presented in Table 7. Eighteen respondents
253 suggested an interface with other electronic systems for previous and current microbiology
254 investigations and results and for drug and clinical information to guide prescribing. There was an
255 apparent demand for flexibility in reporting software to allow reports to be customised locally but
256 also to generate a standard set of reports for reporting to Public Health England in accordance with
257 antimicrobial stewardship guidance for English Hospitals: Start Smart – Then Focus.²²

258

259 **DISCUSSION**

260 This is the first survey of UK infection specialist healthcare professionals evaluating opinions of the
261 potential for e-prescribing software to facilitate antimicrobial stewardship. The two largest health
262 professional groups responsible for AMS are represented and the majority of respondents were
263 experienced in a specialist role. We estimate an approximate response rate of 24% of NHS hospital
264 specialist infection pharmacists and at least 8% of practising UK medical microbiologists.^{23, 24}
265 Responses were included from 68 unique IP addresses representing up to 36% (68/188) of NHS
266 hospital trusts/boards if the questionnaire was completed from the employing hospital's IP

267 address.²⁵⁻²⁸ Teaching hospitals are proportionately over-represented compared with DGHs but
268 there was a good balance of respondents with experience of EPMA systems and those without.
269
270 The prescribing prompt software features ranked of highest priority by respondents were allergy
271 checker, interaction checker and dose checker, which are already incorporated as standard
272 functionality in a number of existing EPMA systems in NHS hospitals.²⁹ The response data suggest an
273 unmet need for AMS-relevant features such as recording of indication and “soft stop” functionality;
274 that are not routinely incorporated into existing EPMA systems. The responses suggest relatively
275 little appetite among UK infection specialists for software features to support restriction of
276 prescribing of selected antimicrobials, possibly reflecting the inter-speciality conflict inherent in such
277 policies, resource implications and the lack of longer-term superiority over persuasive
278 interventions.³⁰ Priorities for active prescription surveillance software features were divided
279 between an emphasis on patient safety (drug-indication mismatch and missed doses) and
280 stewardship (prescriptions for critical antimicrobials and long course lengths). Reports of new or
281 ongoing prescriptions of any antimicrobial were considered lower priority, potentially reflecting the
282 limited resources available to AMS teams to review these prescriptions.³¹ Opinions of the expected
283 impact of the proposed prescribing prompt and active prescription surveillance software features on
284 patient outcomes, public health outcomes and resource use outcomes were overwhelmingly
285 positive. It is particularly striking that more than 90% of respondents considered prescribing prompt
286 software features and active prescription surveillance features either likely or extremely likely to
287 improve patient safety, corroborated by an expectation of improved treatment efficacy and reduced
288 *Clostridium difficile* infection. An improvement in ability to deliver stewardship and more efficient
289 deployment of stewardship resources was also anticipated.
290
291 We found that pharmacists were more likely to prioritise a prescribing prompt to record indication,
292 which may reflect the uncertainty faced by hospital pharmacists when validating new prescriptions

293 for antimicrobials (for safety and effectiveness) prior to authorising dispensing; and the requirement
294 to audit antimicrobial prescribing for adherence to local treatment guidelines.^{22, 32} Pharmacists also
295 prioritised the treatment protocol software feature, consistent with their preference for daily
296 reports of drug-indication mismatch in contrast to medical microbiologists. We found that medical
297 microbiologists were more likely to prioritise prescribing prompts for dose checking and interaction
298 checking in comparison to pharmacists, perhaps indicating differences in undergraduate teaching
299 and endorsing the value of a multi-disciplinary approach to infection management. Respondents
300 from hospitals with experience of EPMA systems ranked the indication prompt feature as relatively
301 more important in comparison to those without, suggesting an unmet need amongst existing
302 software systems.

303

304 When technical aspects of surveillance reports were considered, it is of interest that reports by
305 individual responsible consultant physician were considered of lesser importance than reports by
306 clinical speciality or hospital department. This finding suggests a lack of willingness to employ a
307 “name-and-shame” approach to stewardship and may represent a preference for promoting a sense
308 of collective responsibility amongst clinician colleagues. Freetext comments identified strong user
309 demand for an interface with the microbiology laboratory software system to support selection of
310 effective therapy and de-escalation and to facilitate prompt intervention when patients are
311 prescribed potentially ineffective therapy.

312

313 This cross-sectional survey was designed in accordance with recommended principles of health
314 professional survey design as far as possible within the available resources.^{33, 34} However, a shorter
315 questionnaire may have improved the response rate.³³ The exclusion of data relating to address or
316 employer means that we cannot rule out the possibility that multiple responses may have been

317 submitted by the same individuals and it is likely that multiple respondents from the same Trust had
318 an effect on our findings. We were also unable to collect information on non-responders so the
319 respondent sample is likely to be biased towards more motivated individuals who are engaged with
320 quality improvement and/or information technology. Approximately half of respondents reported
321 experience of EPMA or e-prescribing and this suggests a potential bias towards hospitals with such
322 systems when compared with a survey carried out by Public Health England in 2014 which reported
323 only 17/76 (22%) of respondent hospitals with e-prescribing for at least one inpatient area.³⁵ The
324 questionnaire did not specifically elicit a description of the existing software features of EPMA
325 systems currently installed in NHS hospitals but anecdotal evidence from the research team and
326 from professional networks in the UK suggests that software features to support **AMS** are extremely
327 limited. **Some of the software features proposed in this survey may not be technically possible for**
328 **existing e-prescribing systems and separate data-mining software may be required, particularly for**
329 **prescribing trend surveillance.** Finally, the present questionnaire was primarily distributed by e-mail
330 to members of professional organisations and therefore may not represent the views of non-
331 members.

332
333 The target audience for this survey – consultant medical microbiologists and specialist pharmacists –
334 was deliberate, to focus on individuals most likely to be responsible for stewardship within an NHS
335 hospital organisation. However, other healthcare workers also play an important role in **AMS** at the
336 individual patient level including junior and senior doctors, nurses, non-medical prescribers and
337 ward pharmacists.³⁶⁻⁴¹ Inclusion of these professional groups in user-testing at the design stage of
338 EPMA implementation is likely to be critical to the success of the proposed software features. Future
339 surveys focussing on front-line prescribers and medication administrators are critical.

340

341 The advent of e-prescribing to NHS hospitals represents a unique new opportunity to engage with
342 healthcare professionals to promote safe, effective and proportionate antimicrobial prescribing and

343 to refresh the antimicrobial stewardship message. It must be acknowledged however that with this
344 opportunity also comes new threats to patient safety from prescribing and administration errors as
345 well as potential de-skilling of healthcare professionals.⁴²⁻⁴⁴ The judicious use of educational
346 prompts may facilitate a sustained change in prescribing behaviour but this must be balanced
347 against the recognised risk of “alert fatigue” and competing priorities for e-prescribing system
348 functionality from other medical and surgical specialities.⁴⁵ Successful implementation of the
349 proposed antimicrobial stewardship software features into e-prescribing systems will likely be
350 contingent upon a variety of sociotechnical considerations including seamless integration into the
351 prescribing workflow with minimal time penalties for end-users and full compatibility with existing
352 NHS information technology hardware and software.^{43, 46}

353
354 This survey represents the first attempt to canvas opinion of infection specialists in the UK on the
355 potential for e-prescribing software to support antimicrobial stewardship. **The findings illustrate**
356 **fundamental principles that are equally relevant to health systems in other countries.** The survey
357 results reveal considerable demand for additional software features expressed by the healthcare
358 professionals charged with promoting rational use of antimicrobials and a consensus of anticipated
359 positive impact on patient safety and efficiency outcomes. The survey demonstrates key differences
360 in health professionals’ opinions of different healthcare benefits of EPMA and underscores the need
361 for a multi-disciplinary approach to the development of EPMA system specifications. We trust this
362 information will prove valuable to software manufacturers currently developing e-prescribing
363 systems when prioritising software functionality and systems interface development and potentially
364 to healthcare commissioners when drafting e-prescribing system specifications. Finally, we
365 commend this topic to research funders with a view to funding research into the potential benefits
366 and unintended consequences of e-prescribing system functionality designed to support
367 antimicrobial stewardship.

368

369 **ACKNOWLEDGEMENTS**

370 The authors would like to thank all of the questionnaire respondents, Daniel Hinchley for EPMA
371 expertise and the support of the Royal College of Pathologists and the UK Clinical Pharmacy
372 Association for questionnaire distribution.

373

374 Some of the findings of this research have been published previously in abstract and poster form at
375 the Federation of Infection Societies annual conference in 2015 (Abstract number 0221).

376

377 **FUNDING**

378 This study was carried out as part of our routine work. KH is partially funded by a Health Education
379 Wessex post-doctoral clinical-academic fellowship.

380

381 **TRANSPARENCY DECLARATIONS**

382 None to declare.

383

384 **REFERENCES**

- 385 1. Davies SC. *Annual Report of the Chief Medical Officer, Volume Two, 2011, Infections and the*
386 *rise of antimicrobial resistance*. London: Department of Health, 2013.
- 387 2. Department of Health, Department for Environment Food & Rural Affairs 2013. UK Five Year
388 Antimicrobial Resistance Strategy 2013 to 2018.
389 [https://www.gov.uk/government/publications/uk-5-year-antimicrobial-resistance-](https://www.gov.uk/government/publications/uk-5-year-antimicrobial-resistance-strategy-2013-to-2018)
390 [strategy-2013-to-2018](https://www.gov.uk/government/publications/uk-5-year-antimicrobial-resistance-strategy-2013-to-2018)
- 391 3. NHS England 2016. Commissioning for Quality and Innovation (CQUIN) - Guidance Technical
392 Annex for 2016/17: Gateway Reference 04225. [https://www.england.nhs.uk/nhs-](https://www.england.nhs.uk/nhs-standard-contract/cquin/)
393 [standard-contract/cquin/](https://www.england.nhs.uk/nhs-standard-contract/cquin/)
- 394 4. Department of Health, PricewaterhouseCoopers 2013. A review of the potential benefits from
395 the better use of information and technology in health and social care.
396 [https://www.gov.uk/government/publications/study-on-the-impact-of-digital-](https://www.gov.uk/government/publications/study-on-the-impact-of-digital-technology-in-health-and-social-care)
397 [technology-in-health-and-social-care](https://www.gov.uk/government/publications/study-on-the-impact-of-digital-technology-in-health-and-social-care)
- 398 5. Baysari MT, Oliver K, Egan B, *et al*. Audit and feedback of antibiotic use: utilising electronic
399 prescription data. *Appl Clin Inform* 2013; **4**: 583-95.

- 400 6. Jahansouz F, Lee J, James CL. Enforcement of antimicrobial policy through restrictions built
401 into system for computerized prescriber order entry. *Am J Health Syst Pharm* 2012; **69**:
402 1191.
- 403 7. Lesprit P, Duong T, Girou E, *et al.* Impact of a computer-generated alert system prompting
404 review of antibiotic use in hospitals. *J Antimicrob Chemother* 2009; **63**: 1058-63.
- 405 8. Wang HY, Lu CL, Wu MP, *et al.* Effectiveness of an integrated CPOE decision-supporting system
406 with clinical pharmacist monitoring practice in preventing antibiotic dosing errors. *Int J*
407 *Clin Pharmacol Ther* 2012; **50**: 375-82.
- 408 9. Webber EC, Warhurst HM, Smith SS, *et al.* Conversion of a single-facility pediatric antimicrobial
409 stewardship program to multi-facility application with computerized provider order
410 entry and clinical decision support. *Appl Clin Inform* 2013; **4**: 556-68.
- 411 10. Westphal JF, Jehl F, Javelot H, *et al.* Enhanced physician adherence to antibiotic use guidelines
412 through increased availability of guidelines at the time of drug ordering in hospital
413 setting. *Pharmacoepidemiol Drug Saf* 2011; **20**: 162-8.
- 414 11. Filice GA, Drekonja DM, Thurn JR, *et al.* Use of a computer decision support system and
415 antimicrobial therapy appropriateness. *Infect Control Hosp Epidemiol* 2013; **34**: 558-65.
- 416 12. Nachtigall I, Tafelski S, Deja M, *et al.* Long-term effect of computer-assisted decision support
417 for antibiotic treatment in critically ill patients: a prospective 'before/after' cohort
418 study. *BMJ Open* 2014; **4**: e005370.
- 419 13. Paul M, Andreassen S, Tacconelli E, *et al.* Improving empirical antibiotic treatment using TREAT,
420 a computerized decision support system: cluster randomized trial. *J Antimicrob*
421 *Chemother* 2006; **58**: 1238-45.
- 422 14. Sintchenko V, Iredell JR, Gilbert GL, *et al.* Handheld computer-based decision support reduces
423 patient length of stay and antibiotic prescribing in critical care. *J Am Med Inform Assoc*
424 2005; **12**: 398-402.
- 425 15. Thursky KA, Buising KL, Bak N, *et al.* Reduction of broad-spectrum antibiotic use with
426 computerized decision support in an intensive care unit. *Int J Qual Health Care* 2006;
427 **18**: 224-31.
- 428 16. Yong MK, Buising KL, Cheng AC, *et al.* Improved susceptibility of Gram-negative bacteria in an
429 intensive care unit following implementation of a computerized antibiotic decision
430 support system. *J Antimicrob Chemother* 2010; **65**: 1062-9.
- 431 17. Buising KL, Thursky KA, Robertson MB, *et al.* Electronic antibiotic stewardship--reduced
432 consumption of broad-spectrum antibiotics using a computerized antimicrobial
433 approval system in a hospital setting. *J Antimicrob Chemother* 2008; **62**: 608-16.
- 434 18. Evans RS, Pestotnik SL, Classen DC, *et al.* A computer-assisted management program for
435 antibiotics and other antiinfective agents. *N Engl J Med* 1998; **338**: 232-8.
- 436 19. Chow AL, Lye DC, Arah OA. Mortality Benefits of Antibiotic Computerised Decision Support
437 System: Modifying Effects of Age. *Sci Rep* 2015; **5**: 17346.

- 438 20. Bright TJ. Transforming user needs into functional requirements for an antibiotic clinical
439 decision support system: explicating content analysis for system design. *Appl Clin*
440 *Inform* 2013; **4**: 618-35.
- 441 21. Hsieh HF, Shannon SE. Three approaches to qualitative content analysis. *Qual Health Res* 2005;
442 **15**: 1277-88.
- 443 22. Public Health England 2015. Antimicrobial Stewardship: "Start Smart - Then Focus".
444 [https://www.gov.uk/government/publications/antimicrobial-stewardship-start-smart-](https://www.gov.uk/government/publications/antimicrobial-stewardship-start-smart-then-focus)
445 [then-focus](https://www.gov.uk/government/publications/antimicrobial-stewardship-start-smart-then-focus)
- 446 23. Wickens HJ, Farrell S, Ashiru-Oredope DA, *et al*. The increasing role of pharmacists in
447 antimicrobial stewardship in English hospitals. *J Antimicrob Chemother* 2013; **68**: 2675-
448 81.
- 449 24. Royal College of Pathologists 2015. First Annual Medical Workforce Report 2015.
450 [https://www.rcpath.org/resourceLibrary/first-annual-medical-workforce-report--](https://www.rcpath.org/resourceLibrary/first-annual-medical-workforce-report--2015.html)
451 [2015.html](https://www.rcpath.org/resourceLibrary/first-annual-medical-workforce-report--2015.html)
- 452 25. Health and Social Care Northern Ireland 2016. Directory of Health and Social Care Trusts.
453 <http://online.hscni.net/hospitals/health-and-social-care-trusts/>
- 454 26. Department of Health 2016. Directory of Authorities and Trusts.
455 <http://www.nhs.uk/servicedirectories/pages/acutetrustlisting.aspx>
- 456 27. NHS Scotland 2016. Directory of Organisations. <http://www.show.scot.nhs.uk/organisations/>
- 457 28. NHS Wales 2016. Directory of Services. <http://www.wales.nhs.uk/ourservices/directory/>
- 458 29. Ahmed Z, McLeod MC, Barber N, *et al*. The use and functionality of electronic prescribing
459 systems in english acute NHS trusts: a cross-sectional survey. *PLoS One* 2013; **8**:
460 e80378.
- 461 30. Davey P, Brown E, Charani E, *et al*. Interventions to improve antibiotic prescribing practices for
462 hospital inpatients. *Cochrane Database Syst Rev* 2013; **4**: CD003543.
- 463 31. Hermsen ED, VanSchooneveld TC, Sayles H, *et al*. Implementation of a clinical decision support
464 system for antimicrobial stewardship. *Infect Control Hosp Epidemiol* 2012; **33**: 412-5.
- 465 32. Thakkar K, Gilchrist M, Dickinson E, *et al*. A quality improvement programme to increase
466 compliance with an anti-infective prescribing policy. *J Antimicrob Chemother* 2011; **66**:
467 1916-20.
- 468 33. Burns KE, Duffett M, Kho ME, *et al*. A guide for the design and conduct of self-administered
469 surveys of clinicians. *CMAJ* 2008; **179**: 245-52.
- 470 34. Kelley K, Clark B, Brown V, *et al*. Good practice in the conduct and reporting of survey research.
471 *Int J Qual Health Care* 2003; **15**: 261-6.
- 472 35. ESPAUR 2014. English surveillance programme for antimicrobial utilisation and resistance
473 (ESPAUR) report 2014. [https://www.gov.uk/government/publications/english-](https://www.gov.uk/government/publications/english-surveillance-programme-antimicrobial-utilisation-and-resistance-espaur-report)
474 [surveillance-programme-antimicrobial-utilisation-and-resistance-espaur-report](https://www.gov.uk/government/publications/english-surveillance-programme-antimicrobial-utilisation-and-resistance-espaur-report)

- 475 36. Ansari F, Gray K, Nathwani D, *et al.* Outcomes of an intervention to improve hospital antibiotic
476 prescribing: interrupted time series with segmented regression analysis. *J Antimicrob*
477 *Chemother* 2003; **52**: 842-8.
- 478 37. Charani E, Castro-Sanchez E, Sevdalis N, *et al.* Understanding the determinants of antimicrobial
479 prescribing within hospitals: the role of "prescribing etiquette". *Clin Infect Dis* 2013; **57**:
480 188-96.
- 481 38. Edwards R, Drumright L, Kiernan M, *et al.* Covering more Territory to Fight Resistance:
482 Considering Nurses' Role in Antimicrobial Stewardship. *J Infect Prev* 2011; **12**: 6-10.
- 483 39. Latter S, Smith A, Blenkinsopp A, *et al.* Are nurse and pharmacist independent prescribers
484 making clinically appropriate prescribing decisions? An analysis of consultations. *J*
485 *Health Serv Res Policy* 2012; **17**: 149-56.
- 486 40. Mattick K, Kelly N, Rees C. A window into the lives of junior doctors: narrative interviews
487 exploring antimicrobial prescribing experiences. *J Antimicrob Chemother* 2014; **69**:
488 2274-83.
- 489 41. Wentzel J, van VL, van LM, *et al.* Participatory eHealth development to support nurses in
490 antimicrobial stewardship. *BMC Med Inform Decis Mak* 2014; **14**: 45.
- 491 42. Ash JS, Sittig DF, Dykstra RH, *et al.* Categorizing the unintended sociotechnical consequences
492 of computerized provider order entry. *Int J Med Inform* 2007; **76 Suppl 1**: S21-S27.
- 493 43. Harrison MI, Koppel R, Bar-Lev S. Unintended consequences of information technologies in
494 health care--an interactive sociotechnical analysis. *J Am Med Inform Assoc* 2007; **14**:
495 542-9.
- 496 44. Strom BL, Schinnar R, Abera F, *et al.* Unintended effects of a computerized physician order
497 entry nearly hard-stop alert to prevent a drug interaction: a randomized controlled
498 trial. *Arch Intern Med* 2010; **170**: 1578-83.
- 499 45. Cash JJ. Alert fatigue. *Am J Health Syst Pharm* 2009; **66**: 2098-101.
- 500 46. Zaidi ST, Marriott JL. Barriers and Facilitators to Adoption of a Web-based Antibiotic Decision
501 Support System. *South Med Rev* 2012; **5**: 42-50.
- 502 47. Polk RE, Hohmann SF, Medvedev S, *et al.* Benchmarking risk-adjusted adult antibacterial drug
503 use in 70 US academic medical center hospitals. *Clin Infect Dis* 2011; **53**: 1100-10.
504
505

506 **Table 1. Glossary of key terms used in the survey of opinions of infection specialists on electronic**
 507 **prescribing and antimicrobial stewardship**

Term	Explanation
Prescribing alert / prompt	The prescriber will be alerted via a “pop-up” message – an “alert or prompt” – e.g. if attempting to prescribe an antimicrobial which is contra-indicated because of an allergy or a drug interaction
Active prescription surveillance	<p>Active prescription surveillance refers to the application of surveillance data in real-time for identification of patients currently prescribed antimicrobial therapy. Software features allow prioritisation of patients for intervention by the antimicrobial stewardship team (AST).</p> <p>Active prescription surveillance reports would typically include: patient name, date of birth, hospital number, inpatient location in the hospital, drug name, drug dose, start date, stop date (if specified), prescriber and responsible senior physician.</p>
Prescribing trend surveillance	Prescribing trend surveillance refers to the review of retrospective data relating to antimicrobial prescribing and administration – typically as trends over time. Prescribing trend surveillance allows continuous monitoring of performance for the purposes of controls assurance and for evaluating the impact of stewardship interventions.
Order Sets	This software feature allows the prescriber to select an infection (e.g. pneumonia, community-acquired, severe) and the system will automatically populate the prescription with the locally pre-defined treatment regimen (single drug or combination of drugs) at standard doses.
Critical antimicrobial	An antimicrobial may be designated “critical” by a hospital AST according to local priorities – for example, broad-spectrum antimicrobials such as carbapenems or antimicrobials with a narrow therapeutic range such as colistin. A prescriber may be alerted when prescribing a critical antimicrobial with an appropriate locally-defined message containing details of actions required when prescribing.
Restricted antimicrobial	An antimicrobial may be designated “restricted” by a hospital AST on grounds of financial cost, propensity to predispose to <i>Clostridium difficile</i> infection or local decision to reserve for multidrug-resistant infections. Prescribing of restricted antimicrobials requires pre-authorisation by a medical microbiologist or infectious diseases physician (“restricted antimicrobial authorisation”) or prescribing is limited by the prescribing software to senior clinicians (“restricted antimicrobial block”).


Soft Stops	This software feature allows the prescriber to nominate a date when the antimicrobial prescription should be reviewed with a view to stopping, changing treatment or switching route of administration to oral. After the review date has passed, the drug will remain visible and available to nursing staff to administer but will be prominently highlighted as being past the review (soft stop) date
Blood level monitoring order set	When a relevant drug is prescribed, the EPMA system will automatically pair the drug prescription with an order for a blood specimen to be taken at an appropriate time post-dose.
Drug-indication mismatch	A mismatch occurs when a prescribed antimicrobial is not appropriate or unauthorised for the recorded indication/provisional diagnosis.
Days of Therapy (DOTs)	One DOT represents the administration of a single systemic antimicrobial on a given day regardless of the number of doses administered or dosage strength. For example, administration of ceftriaxone as 4g once-daily or as 2g twice-daily for one day would both represent 1 DOT. A single patient receiving both vancomycin and ceftazidime during the same day would be recorded as receiving 2 DOTs (1 of vancomycin and 1 of ceftazidime). ⁴⁷
Length of Therapy (LOT)	LOT refers to antimicrobial course length and is the number of sequential days that a patient receives any systemic antimicrobial drug(s), irrespective of the number of different drugs. ⁴⁷ A prescription of intravenous piperacillin-tazobactam and vancomycin for 2 days followed by oral co-amoxiclav for 5 days corresponds to a LOT of 7 days.
Point Prevalence	Point prevalence is the proportion of hospital patients active on the EPMA system that are prescribed any antimicrobial at a specific point in time (for example at noon on the first day of each month).

508

509

510


Figure 1. Demographic profile of respondents: professional group and years of experience in specialist infection role



511

512

513



514

515

516 Table 2. Prescribing Prompt software features ranked in order of respondent-assigned priority

Software feature	Number of responses	Essential	High priority	Medium priority	Low priority	Not a priority
Allergy checker	142	80.3%	14.8%	3.5%	1.4%	0.0%
Indication prompt	139	56.8%	30.9%	10.8%	1.4%	0.0%
Interaction checker	143	45.5%	35.7%	14.7%	4.2%	0.0%
Soft stop	141	38.3%	51.1%	7.1%	2.8%	0.7%
Blood level prompt	140	35.0%	46.4%	15.7%	2.9%	0.0%
Dose checker (children)	142	33.8%	44.4%	19.0%	2.1%	0.7%
Dose checker (adults)	141	25.5%	48.2%	22.0%	3.5%	0.7%
Critical antimicrobial prompt	141	24.1%	48.2%	21.3%	4.3%	2.1%
Indication order set	143	21.7%	45.5%	25.2%	4.9%	2.8%
Blood level order set	140	21.4%	39.3%	29.3%	9.3%	0.7%
Restricted antimicrobial require authorisation	142	18.3%	25.4%	30.3%	17.6%	8.5%
Restricted antimicrobial block by prescriber	140	15.7%	31.4%	26.4%	16.4%	10.0%

517

518

519 **Table 3. Differences in software feature priority assignment between respondent groups found to**
 520 **be statistically significant**

Domain / Respondent group	Software feature	Respondent group (% of responses rated essential)		Mann-Whitney U test p-value
		Pharmacists	Medical microbiologists	
Prescribing prompts	Allergy checker	90%	69%	p=0.003 (n=68, 52)
	Indication prompt	73%	39%	p<0.001 (n=67, 51)
	Treatment protocols	28%	15%	p=0.003 (n=68, 53)
	Dose checker (adults)	16%	34%	p=0.023 (n=68, 53)
	Interaction checker	34%	51%	p=0.047 (n=68, 53)
Active prescription surveillance	Drug-indication mismatch	35%	25%	p=0.031 (n=65, 49)
	Long IV/oral course	31%	24%	p=0.041 (n=65, 50)
EPMA experience		EPMA-experienced	Non EPMA-experienced	
Prescribing prompts	Indication prompt	66%	47%	p=0.049 (n=68, 68)
	Restricted antimicrobial block	12%	17%	p=0.011 (n=67, 70)
	Dose checker (children)	26%	39%	p=0.024 (n=68, 70)
	Blood level monitoring alert	24%	44%	p=0.033 (n=67, 70)
Active prescription	Daily report of newly-prescribed critical antimicrobials	64%	40%	p=0.015 (n=64, 68)

surveillance	Daily report of any newly-prescribed antimicrobial	23%	16%	p=0.024 (n=64, 68)
Hospital type		Teaching	District General	
Prescribing trend surveillance	Report of trends in proportion of stat doses where administration was delayed	28%	18%	p=0.034 (n=55, 65)


521

522

523

Figure 3. Respondent opinions of the likely impact of Prescribing Prompt software features

524

on clinical, microbiological and process outcomes

525

526

527

528 **Table 4. Active Prescription Surveillance software features ranked in order of respondent-**
 529 **assigned priority**


Software feature	Number of responses	Essential	High priority	Medium priority	Low priority	Not a priority
New Rx of critical drug	135	51.9%	41.5%	6.7%	0.0%	0.0%
Ongoing Rx of critical drug	135	42.2%	42.2%	15.6%	0.0%	0.0%
Drug-indication mismatch	134	31.3%	47.8%	17.9%	3.0%	0.0%
Long IV/oral course	135	28.9%	54.8%	14.8%	0.7%	0.7%
Missed Abx doses	132	26.5%	43.9%	22.7%	6.1%	0.8%
Long IV course	132	25.0%	59.8%	14.4%	0.8%	0.0%
High-dose aminoglycoside	133	23.3%	40.6%	25.6%	9.0%	1.5%
New Rx for sepsis of unknown origin	134	20.1%	57.5%	19.4%	1.5%	1.5%
New Rx of any antibiotic	136	19.1%	27.9%	33.1%	17.6%	2.2%
Ongoing Rx of any antibiotic	133	13.5%	30.8%	36.1%	15.0%	4.5%
New Rx for diagnosis of interest	135	13.3%	51.9%	30.4%	3.0%	1.5%

530

531

532

533 **Figure 4. Respondent opinions of the likely impact of Active Prescription Surveillance software**
534 **features on clinical, microbiological and process outcomes**



535

536

537 **Table 5. Prescribing Trend Surveillance software features ranked in order of respondent-assigned**
 538 **priority**


Software feature	Number of responses	Essential	High priority	Medium priority	Low priority	Not a priority
Trends in point prevalence	130	29.2%	44.6%	23.1%	2.3%	0.8%
Trends in missed doses	130	26.9%	45.4%	24.6%	2.3%	0.8%
Trends in delayed stat doses	130	23.1%	53.8%	19.2%	3.8%	0.0%
Trends in total days of therapy (DOTs)	130	13.1%	39.2%	37.7%	7.7%	2.3%
Trends in average length of therapy (LOT)	131	13.0%	53.4%	29.0%	3.8%	0.8%

539

540

541

542 **Figure 5: Respondent opinions of the likely impact of Prescribing Trend Surveillance software**
 543 **features on clinical, microbiological and process outcomes**



544

545

546 **Table 6: Respondent opinions of technical aspects of prescribing trend surveillance reporting**
 547 **software features ranked in order of respondent-assigned priority**

	Response Count	Importance attributed by respondents				
		Very high	High	Moderate	Some	None
ACTIVITY DENOMINATOR						
EPMA patient days (total number of patients multiplied by number of days)	130	16.2%	40.0%	31.5%	10.8%	1.5%
EPMA admissions (new patients)	130	13.8%	38.5%	36.2%	10.8%	0.8%
REPORT TIME INTERVALS						
Annually	130	48.5%	31.5%	13.1%	3.8%	3.1%
Quarterly	130	40.0%	42.3%	13.8%	2.3%	1.5%
Monthly	130	24.6%	36.9%	29.2%	6.9%	2.3%
Weekly	129	7.8%	20.9%	27.9%	28.7%	14.7%
Daily	130	4.6%	15.4%	22.3%	26.2%	31.5%
HOSPITAL SUBDIVISIONS						
Whole hospital	129	49.6%	38.8%	6.2%	4.7%	0.8%
Clinical speciality	128	42.2%	41.4%	11.7%	3.9%	0.8%
Hospital departments	128	40.6%	36.7%	16.4%	4.7%	1.6%
Wards	128	32.8%	39.1%	21.1%	5.5%	1.6%
Responsible consultant physician	129	32.6%	37.2%	20.2%	9.3%	0.8%

DRUG GROUPINGS						
Individual drugs	129	48.8%	36.4%	10.9%	2.3%	1.6%
Drug class (e.g. macrolides)	128	41.4%	41.4%	13.3%	3.9%	0.0%
Locally-defined drug group (e.g. broad-spectrum, narrow-spectrum)	130	40.0%	38.5%	16.9%	4.6%	0.0%
Antibacterials, antifungals, antivirals, antiparasitics	127	33.9%	37.0%	15.7%	13.4%	0.0%
All antimicrobials	130	30.0%	36.9%	19.2%	11.5%	2.3%
By route of administration	129	24.0%	40.3%	24.8%	8.5%	2.3%

548

549

550

551 **Table 7. Thematic analysis of freetext narrative responses to the question: “Do you have any**
 552 **other suggestions for potential functionality for electronic prescribing and medicines**
 553 **administration systems?”**

Theme	Frequency	Details of additional user requirements
Microbiology laboratory system interface	13	• Susceptibility testing – prescription conflict (“drug-bug mismatch”)
		• Previous microbiology including healthcare-associated infections
Reporting functions	9	• Flexibility of reporting – capacity to customise reports locally
		• Reporting to national standard (Start Smart – Then Focus)
		• Defined daily doses in addition to DOTs
Clinical information system interface	5	• Link to guidelines
		• Drug information: adverse effects, drug administration, drug monitoring
		• Disease severity scoring systems
Restriction systems	5	• Authorisation codes
		• Authorisation by named specialist
		• System access restricted to trained prescribers
		• Compulsory recording of indication
Additional narrative fields	5	• Infection specialist advice
		• Justification for off-guideline prescribing
		• Precise nature of drug allergy
		• Reasons for missed doses
Soft stops / review dates	4	• Block administration until review
		• Patient safety of automatic prescription stop
Dosing support	3	• Dosing by age, weight and renal function
Drug history	3	• Primary care and previous hospital admissions
Stat doses	3	• Automatic associated stat dose and appropriately spaced maintenance dose
		• Stat dose remains visible if delayed
Miscellaneous	19	

554

555

Electronic Prescribing & Antibiotic Stewardship

Survey of opinions of infection specialists on electronic prescribing and antibiotic stewardship.

The aim of this research is to IMPROVE THE DESIGN OF ELECTRONIC PRESCRIBING SYSTEMS TO PROMOTE ANTIBIOTIC STEWARDSHIP.

We would be very grateful if infection specialists could take a few moments to respond to this brief but important survey. There are 4 pages with a total of 42 questions and completion takes 10-12 minutes.

Please respond EVEN IF YOU DO NOT CURRENTLY HAVE AN E-PRESCRIBING SYSTEM.

The results will be fed back to the software manufacturers, NHS England, Dept of Health, and published in a pharmacy / infection / health informatics journal.

This research does not need NHS Research Ethics Committee approval for sites in England, Scotland, Wales or Northern Ireland <http://www.hra-decisiontools.org.uk/ethics/>

Sincere thanks.

Debbie Cumming (Isle of Wight) & Kieran Hand (Southampton)

1. Professional Group

- Pharmacist (infection specialist)
- Pharmacist (not infection specialist)
- Pharmacy technician
- Medical Microbiologist
- Infectious Diseases Physician

Other (please specify)

2. Experience in specialist infection role

- 0-1 year
- 1-2 years
- 2-5 years
- 5-10 years
- >10 years
- N/A (non-specialist)

3. Acute hospital setting

- Teaching (trusts with an attached undergraduate medical school)
- District General Hospital
- Specialised (trusts with very restricted specialties, such as orthopaedic and children's trusts)
- Independent (non NHS)

4. Hospital size

- Very large (>1500 beds)
- Large (1001-1500 beds)
- Medium (501-1000 beds)
- Small (<501 beds)

5. Does your hospital currently use an electronic prescribing and/or medicines administration (EPMA) system for SOME or ALL wards?

- Yes, EPMA on all wards
- Yes, EPMA on some wards
- Yes, but electronic prescribing only (no medicines administration function)
- Yes, but ICU/Oncology system(s) only.
- No, but expected within 5 years
- No, NOT expected within 5 years

6. How long has your EPMA or electronic prescribing system been in use?

- 0-1 year
- 1-2 years
- 2-5 years
- 5-10 years
- >10 years
- N/A

only

Electronic Prescribing & Antibiotic Stewardship**Section 1: PRESCRIBING PROMPTS**

Please indicate the priority you would place upon each of the following options.

7. TREATMENT PROTOCOLS / ORDER SETS -

The prescriber has an opportunity to select an infection (e.g. pneumonia, community-acquired, severe) and the system will automatically populate the prescription with the locally pre-defined treatment regimen (single drug or combination of drugs) and standard doses.

Not a priority	Low priority	Medium priority	High priority	Essential
<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

8. ALLERGY CHECKER -

The prescriber will be alerted via a pop-up message if attempting to prescribe an antimicrobial from the same class of drugs as a previously recorded allergy.

Not a priority	Low priority	Medium priority	High priority	Essential
<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

9. INTERACTION CHECKER -

The prescriber will be alerted via a pop-up message if attempting to prescribe an antimicrobial that interacts in a clinically-significant manner with any of the currently-prescribed drugs.

Not a priority	Low priority	Medium priority	High priority	Essential
<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

10. DOSE CHECKER (ADULTS) -

The prescriber will be alerted via a pop-up message if attempting to prescribe a dose of antimicrobial that is above or below a pre-specified dose range for adult inpatients.

Not a priority	Low priority	Medium priority	High priority	Essential
<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

11. DOSE CHECKER (CHILDREN) -

The prescriber will be alerted via a pop-up message if attempting to prescribe a dose of antimicrobial that is above or below a pre-specified dose range for inpatient age or weight.

Not a priority	Low priority	Medium priority	High priority	Essential
<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

12. CRITICAL ANTIMICROBIAL ALERT -

The prescriber will be alerted via a pop-up message if attempting to prescribe certain locally-defined critical antimicrobials (e.g. carbapenems), with brief details of actions required. The prescriber will NOT be blocked from prescribing the critical antimicrobial.

Not a priority	Low priority	Medium priority	High priority	Essential
<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

13. RESTRICTED ANTIMICROBIAL BLOCK -

Prescribing of restricted antimicrobials will be limited to certain groups of prescriber (e.g. consultant) and blocked for unauthorised prescribers.

Not a priority	Low priority	Medium priority	High priority	Essential
<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

14. RESTRICTED ANTIMICROBIAL AUTHORISATION -

Prescribing of restricted antimicrobials will require authorisation by an infection specialist or senior doctor (e.g. by entering a release code).

Not a priority	Low priority	Medium priority	High priority	Essential
<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

15. SOFT STOPS -

The system will allow the prescriber to nominate a date when the antimicrobial prescription should be reviewed with a view to stopping, changing treatment or switch to oral. After the review date has passed, the drug will remain visible and available to nursing staff to administer but will be prominently highlighted as being past the review (soft stop) date.

Not a priority	Low priority	Medium priority	High priority	Essential
<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

16. INDICATION PROMPT -

When selecting an antimicrobial, the prescriber will be required to complete a mandatory field for indication/provisional diagnosis from a drop-down list of body systems or indications. This data field may be edited later when the indication is confirmed. 'Sepsis of undetermined origin' should be an option.

Not a priority	Low priority	Medium priority	High priority	Essential
<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

17. BLOOD LEVEL MONITORING ALERT -

The prescriber will be alerted via a pop-up message that they have selected a drug which requires blood level monitoring and brief details of actions required.

Not a priority	Low priority	Medium priority	High priority	Essential
<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

18. BLOOD LEVEL MONITORING PROTOCOL / ORDER SET -

When a relevant drug is prescribed, the system will automatically pair the drug prescription with a “prescription” for a blood specimen to be taken at an appropriate time post-dose.

Not a priority	Low priority	Medium priority	High priority	Essential
<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

19. If some or all of these PRESCRIBING PROMPT functionalities are available in an electronic prescribing system, please indicate the likelihood of a positive impact upon the following outcomes:

	Extremely unlikely	Unlikely	Neutral	Likely	Extremely likely
Efficacy of treatment improved	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Safety improved	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Antimicrobial resistance reduced	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Expenditure on drugs reduced	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Risk of Clostridium difficile reduced	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Ability to deliver stewardship improved	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Work efficiency improved	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

Peer review only

Electronic Prescribing & Antibiotic Stewardship

Section 2: ACTIVE SURVEILLANCE

Active surveillance reports should be available to specialist pharmacists and infection doctors and may be used to plan stewardship ward rounds or telephone consults.

Reports would typically include: patient name, date of birth, hospital number, inpatient location in the hospital, drug name, drug dose, start date, stop date (if specified), prescriber and responsible consultant.

Please indicate the priority you would place upon each of the following options.

20. Daily report of NEW prescriptions of CRITICAL antimicrobials -

Generate a list of inpatients newly-prescribed, locally-defined, CRITICAL antimicrobials (e.g. carbapenems) within the last 24 hours (excluding stat doses).

Not a priority

Low priority

Medium priority

High priority

Essential

21. Daily report of NEW prescriptions of ALL antimicrobials -

Generate a list of inpatients newly-prescribed ANY antimicrobial within the last 24 hours (excluding stat doses).

Not a priority

Low priority

Medium priority

High priority

Essential

22. Daily report of ONGOING prescriptions of CRITICAL antimicrobials -

Generate a list of all inpatients currently prescribed CRITICAL antimicrobials (e.g. carbapenems).

Not a priority

Low priority

Medium priority

High priority

Essential

23. Daily report of ONGOING prescriptions of ALL antimicrobials -

Generate a list of all inpatients currently prescribed ANY antimicrobial.

Not a priority

Low priority

Medium priority

High priority

Essential

24. Daily report of DRUG-INDICATION MISMATCH -

Generate a list of all inpatients newly-prescribed an antimicrobial within the last 24 hours that is not authorised for the recorded indication/provisional diagnosis.

Not a priority

Low priority

Medium priority

High priority

Essential

25. Daily report of prescriptions for SEPSIS OF UNDETERMINED ORIGIN -

Generate a list of all inpatients newly-prescribed an antimicrobial within the last 24 hours with a recorded indication/provisional diagnosis of 'sepsis of undetermined origin'.

Not a priority	Low priority	Medium priority	High priority	Essential
<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

26. Daily report of prescriptions for DIAGNOSIS OF INTEREST -

Generate a list of all inpatients newly-prescribed an antimicrobial within the last 24 hours with a recorded indication/provisional diagnosis of interest locally (e.g. septic shock).

Not a priority	Low priority	Medium priority	High priority	Essential
<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

27. Daily report of MISSED DOSES -

Generate a list of all inpatients currently prescribed ANY antimicrobial with a missed dose recorded in the previous 24 hours, including REASON FOR MISSED DOSE (if recorded).

Not a priority	Low priority	Medium priority	High priority	Essential
<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

28. Daily report of LONG INTRAVENOUS COURSE LENGTH -

Generate a list of all inpatients currently prescribed an INTRAVENOUS antimicrobial started >72 hours ago. 72-hour cut-off may be modified locally.

Not a priority	Low priority	Medium priority	High priority	Essential
<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

29. Daily report of LONG TOTAL COURSE LENGTH -

Generate a list of all inpatients currently on day 8 or longer of sequential therapy with any drug from BNF Chapter 5 (antimicrobials) by any route of administration. Day 8 cut-off may be modified locally.

Not a priority	Low priority	Medium priority	High priority	Essential
<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

30. Daily report of HIGH-DOSE AMINOGLYCOSIDE prescriptions -

Generate a list of inpatients prescribed doses of gentamicin/tobramycin/amikacin above a locally-defined total daily dose threshold (e.g. 300mg/300mg/1000mg).

Not a priority	Low priority	Medium priority	High priority	Essential
<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

31. If some or all of these ACTIVE SURVEILLANCE functionalities are available in an electronic prescribing system, please indicate the impact you anticipate on the following outcomes:

	Extremely unlikely	Unlikely	Neutral	Likely	Extremely likely
Efficacy of treatment improved	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Safety improved	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Antimicrobial resistance reduced	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Expenditure on drugs reduced	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Risk of Clostridium difficile reduced	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Ability to deliver stewardship improved	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Work efficiency improved	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

for peer review only

Electronic Prescribing & Antibiotic Stewardship

Section 3: PASSIVE SURVEILLANCE

Reports should be available to named pharmacists and infection doctors and may be used to monitor performance over monthly, quarterly or annual time trends for a date range specified by the user.

Please indicate the priority you would place upon each of the following functionality options for electronic prescribing and medicines administration systems.

32. Antimicrobial days of therapy (DOTs) -

Generate a report (line trend over time) of the number days of therapy (DOTs) for all antimicrobials prescribed during the selected time interval (e.g. total DOTs per month).

One DOT represents the administration of a single agent on a given day regardless of the number of doses administered or dosage strength. For example, administration of ceftriaxone as 4g od or as 2g bd would both represent 1 DOT. A single patient receiving both vancomycin and ceftazidime would be recorded as receiving 2 DOTs (1 of vancomycin and 1 of ceftazidime) [Polk RE et al, CID 2011].

Not a priority

Low priority

Medium priority

High priority

Essential

33. Antimicrobial length of therapy (LOTs) -

Generate a report (line trend over time) with the AVERAGE length of therapy (LOT) for all antimicrobial courses during the selected time interval (e.g. average LOT per month).

The LOT is the number of sequential days that a patient receives ANY systemic antimicrobial drug(s) from BNF Chapter 5, irrespective of the number of different drugs [Polk RE et al, CID 2011].

Not a priority

Low priority

Medium priority

High priority

Essential

34. Percentage of inpatients prescribed antimicrobials (POINT PREVALENCE) -

Generate a report (line trend over time) with the percentage of all patients on the EPMA system during the selected time interval who were prescribed at least one dose of a drug from BNF Chapter 5 (antimicrobials).

Not a priority

Low priority

Medium priority

High priority

Essential

35. DELAYED STAT DOSES -

Generate a report (line trend over time) with the number of incidents where a patient is prescribed a stat dose of a drug from BNF Chapter 5 (antimicrobials) and administration is delayed by >1hour from the prescribed time for the selected reporting time interval.

Not a priority

Low priority

Medium priority

High priority

Essential

36. MISSED DOSES of antimicrobials -

Generate a report (line trend over time) of the number of missed doses of a drug from BNF Chapter 5 (antimicrobials) for the selected reporting time interval.

Not a priority	Low priority	Medium priority	High priority	Essential
<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

37. For passive surveillance reports described above (DOTs and LOTs), how important is it to be able to adjust reports for the following activity denominators?

	No importance	Some importance	Moderate importance	High importance	Very high importance
EPMA patient days (total number of patients multiplied by number of days)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
EPMA admissions (new patients)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

38. For passive surveillance reports described above (DOTs, LOTs and Point Prevalence), how important is it to be able to generate reports at the following time intervals?

	No importance	Some importance	Moderate importance	High importance	Very high importance
Annually	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Quarterly	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Monthly	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Weekly	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Daily	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

39. For passive surveillance reports described above (DOTs, LOTs and Point Prevalence), how important is it to be able to generate reports for the following subdivisions?

	No importance	Some importance	Moderate importance	High importance	Very high importance
Whole hospital	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Hospital departments	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Wards	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Clinical speciality	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Responsible consultant doctor	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

40. For passive surveillance reports described above (DOTs, LOTs and Point Prevalence), how important is it to be able to generate reports for the following drug groups?

	No importance	Some importance	Moderate importance	High importance	Very high importance
All antimicrobials (BNF Chapter 5)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Antibacterials, antifungals, antivirals, antiparasitics (BNF Chapter 5.1 etc)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Drug class (e.g. macrolides)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Drug group (e.g. broad-spectrum, narrow-spectrum - locally defined)	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Individual drugs	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
By route of administration	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

41. If some or all of these PASSIVE SURVEILLANCE functionalities are available in an electronic prescribing system, please indicate the impact you anticipate on the following outcomes:

	Extremely unlikely	Unlikely	Neutral	Likely	Extremely likely
Efficacy of treatment improved	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Safety improved	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Antimicrobial resistance reduced	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Expenditure on drugs reduced	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Risk of Clostridium difficile reduced	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Ability to deliver stewardship improved	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Work efficiency improved	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

42. We are extremely grateful to you for taking the time to participate in this survey.

We hope the results will influence the design of electronic prescribing systems and improve the care of patients with infection.

DO YOU HAVE ANY OTHER SUGGESTIONS FOR POTENTIAL FUNCTIONALITY FOR ELECTRONIC PRESCRIBING AND MEDICINES ADMINISTRATION SYSTEMS? Please describe your ideas below.

Confidential: for peer review only